Moreover, C225-ILs-DOX exhibited significantly superior antitumor efficacy when compared to the corresponding free or non-targeted liposomal DOX in another two EGFR-overexpressing tumor xenograft models.194 In a phase I clinical trial (ClinicalTrials.gov Identifier: NCT01702129) conducted by researchers from the University Hospital of Basel, 26 patients with EGFR-overexpressing refractory solid malignancies were enrolled and treated with escalating doses of C225-ILs-DOX. The gene discussed is EGFR; the disease is neoplasm.